Waylivra is a medicine used to treat familial chylomicronaemia syndrome (FCS), a genetic condition that gives rise to high levels of fats called triglycerides in the blood. Excess fat builds up in various parts of the body and leads to symptoms including abdominal pain (belly ache), deposits of fat under the skin and pancreatitis (inflammation of the pancreas). Waylivra, along with a low fat diet, is used to reduce triglyceride blood levels in patients with FCS that has been confirmed by genetic testing. It is only given to patients in whom other medicines to reduce triglycerides have not worked and who are at high risk of developing pancreatitis. FCS is rare, and Waylivra was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 19 February 2014. Waylivra contains the active substance volanesorsen.
Therapeutic Indication
### Therapeutic indication Waylivra is indicated as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.
Therapeutic Area (MeSH)
ATC Code
C10AX18
ATC Item
volanesorsen
Pharmacotherapeutic Group
Other lipid modifying agents
Active Substance (Summary)
INN / Common Names
EMA Name
Waylivra
Medicine Name
Waylivra
Aliases
N/A
